

COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

WASHINGTON, DC—APRIL 29, 2019

Course Chairs	
Henry Masur, MD Clinical Professor of Medicine George Washington University Washington, DC	<i>Dr Masur has no relevant financial affiliations to disclose. (Updated 04/02/19)</i>
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 03/29/19)</i>
Speakers	
R. Douglas Bruce, MD, MA, MS Associate Clinical Professor of Medicine Yale University New Haven, Connecticut	<i>Dr Bruce has no relevant financial affiliations to disclose. (Updated 04/08/19)</i>
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York, New York	<i>Dr Gulick has no relevant financial affiliations to disclose. (Updated 04/03/18)</i>
Jeanne Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Marrazzo has received research grants from Merck & Co, Inc, and Cepheid; served as an advisor to Gilead Sciences, Inc, and BioFire Diagnostics, and served on a data safety monitoring board for Gilead Sciences, Inc. (Updated 04/09/19)</i>
Jessica Merlin, MD, PhD, MBA Associate Professor of Medicine University of Pittsburgh Pittsburgh, Pennsylvania	<i>Dr Merlin has no relevant financial affiliations to disclose. (Updated 02/25/19)</i>
Irini Sereti, MD, MHS Senior Clinical Investigator National Institute of Allergy and Infectious Disease National Institutes of Health Bethesda, Maryland	<i>Dr Sereti has no relevant financial affiliations to disclose. (Updated 11/16/18)</i>
IAS–USA CME Planner and Reviewer	
Donna M. Jacobsen Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 04/22/19)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.	
IAS–USA Viral Hepatitis Advisory Board	
The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/ for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.	